Biocon jumps as its arm launches Nepexto in Australia
Biocon is currently trading at Rs. 393.95, up by 6.90 points or 1.78% from its previous closing of Rs. 387.05 on the BSE.
The scrip opened at Rs. 384.80 and has touched a high and low of Rs. 394.50 and Rs. 384.80 respectively. So far 37199 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 405.90 on 18-Jul-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 405.90 and Rs. 384.80 respectively. The current market cap of the company is Rs. 52669.68 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.86% and 16.68% respectively.
Biocon’s subsidiary -- Biocon Biologics (BBL) has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia. Nepexto will be promoted by Generic Health, its local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in Australia.
Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen its immunology offering.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
